Galderma to Acquire ZO Skin Health for $1.5 Billion

Swiss dermatology company Galderma has agreed to acquire US-based professional skincare brand ZO Skin Health for an enterprise value of $1.5 billion, strengthening its position in the medical-grade skincare market. Announced on October 14, 2026, the all-cash transaction will give Galderma 100% ownership of ZO Skin Health, whose products are distributed through physicians, medical spas and other professional skincare channels. The deal is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions.

The acquisition brings together ZO Skin Health’s physician-dispensed skincare products and Galderma’s existing portfolio, which includes Cetaphil and Alastin. ZO recorded approximately $330 million in net sales in the 12 months to June 2026, according to the acquisition announcement. Galderma expects the transaction to be neutral to core earnings per share in the first full year following completion, while planning additional commercial investment to support the brand’s next phase of growth.

Key Takeaways

• Deal value: Galderma will acquire 100% of ZO Skin Health for an enterprise value of $1.5 billion.
• All-cash transaction: The purchase will be funded through a combination of existing cash reserves and bank financing.
• ZO Skin Health revenue: The US brand generated approximately $330 million in net sales in the 12 months to June 2026.
• Global distribution: ZO has more than 40 products and serves over 16,500 physician, medical spa and online accounts across more than 40 countries.
• Portfolio expansion: The acquisition complements Galderma’s existing Cetaphil and Alastin skincare brands.
• Expected completion: The deal is targeted to close in Q4 2026 or early 2027, subject to approvals.
• Earnings outlook: Galderma expects the acquisition to be neutral to core earnings per share in the first full year after closing.

Galderma Agrees to Buy ZO Skin Health for $1.5 Billion

The acquisition expands Galderma’s presence in professional skincare, a segment in which products are often recommended or distributed by dermatologists, plastic surgeons and other skincare professionals.

ZO Skin Health was founded by dermatologist Dr. Zein Obagi in 2007 and is headquartered in Irvine, California. Its product portfolio includes cleansers, serums, exfoliators, toners and other products designed to be used as part of structured skincare routines.

Galderma will acquire the entire business from its shareholders, including funds managed by Blackstone Tactical Opportunities and the Obagi family. Blackstone acquired ZO in 2020 through its tactical opportunities investment fund.

The $1.5 billion enterprise value represents the agreed value of the business, rather than a simple measure of the cash paid to a single seller. The transaction is structured as an all-cash acquisition, with funding expected to come from Galderma’s existing cash reserves and bank financing, subject to customary adjustments.

For Galderma, the purchase offers an opportunity to expand its dermatological skincare portfolio with a brand that already has an established professional distribution network. For ZO, joining a global dermatology group could provide additional resources for product development, education and international expansion.

ZO Skin Health’s Revenue and Global Reach

ZO Skin Health has built a business around professional skincare products and structured daily regimens. Its distribution model gives it access to consumers through healthcare professionals and medical spas, alongside online channels.

The company’s existing reach is an important part of the acquisition rationale. Galderma will gain an established brand, a broad product range and a network of professional accounts rather than having to build an equivalent business from scratch.

ZO Skin Health metric	Reported figure
Acquisition enterprise value	$1.5 billion
Net sales, trailing 12 months to June 2026	Approximately $330 million
Product portfolio	More than 40 products
Physician, medical spa and online accounts	More than 16,500
Countries served	More than 40
Founded	2007
Headquarters	Irvine, California, US

Source: Galderma’s acquisition announcement and related reporting. Net sales are for the 12 months to June 2026, not a full-year forecast.

The $330 million revenue figure provides a useful indication of the business’s existing scale. Dividing the $1.5 billion enterprise value by that sales figure produces a rough ratio of about 4.5 times trailing sales. This is an indicative calculation, not a complete valuation assessment: enterprise value and equity value differ, while profitability, growth expectations, debt and future investment requirements also influence whether a deal is attractive.

The acquisition announcement did not establish that revenue or profits would automatically accelerate after the transaction. Galderma’s ability to improve ZO’s performance will depend on execution, commercial investment, product demand and the economics of its distribution channels.

Why Galderma Is Expanding Its Skincare Portfolio

Galderma specialises in dermatology and operates across dermatological skincare, therapeutic dermatology and injectable aesthetics. Its portfolio includes Cetaphil, Alastin, acne treatments such as Differin and Epiduo, the Dysport neurotoxin and Restylane dermal fillers.

The addition of ZO Skin Health strengthens the company’s professional skincare offering, particularly products sold through physicians and other skincare specialists.

The strategic logic is based on complementary positioning. ZO’s multi-step daily skincare regimens are built around ingredients including retinol and acids, while Alastin has a portfolio focused on regenerative skincare and products used around aesthetic procedures. Galderma believes the two brands can serve different but related needs among healthcare professionals and their patients.

The acquisition could also give Galderma more opportunities to use its existing commercial infrastructure, research capabilities and international presence to support ZO’s expansion.

However, combining two brands does not guarantee that every product or distribution channel will generate additional sales. The company will need to preserve each brand’s identity, manage relationships with professional distributors and ensure that commercial expansion does not undermine product positioning.

The Growing Market for Physician-Dispensed Skincare

The acquisition comes amid competition for skincare brands that combine professional distribution with a science-based product proposition.

Traditional skincare products are often sold directly to consumers through supermarkets, pharmacies, beauty retailers and online platforms. Physician-dispensed brands use a different route to market: products may be recommended or sold through dermatologists, plastic surgeons, medical spas and other professional channels.

This model can create closer relationships between brands and skincare professionals. It can also support regimen-based sales, in which consumers purchase several complementary products rather than a single item.

For companies, professional distribution offers a way to differentiate products in a crowded skincare market. Brands may compete on formulation, clinical research, practitioner education, product positioning and the consistency of their recommended routines.

The model has limitations. Professional distribution can make customer acquisition more dependent on practitioners, while premium pricing may restrict the potential customer base. Brands must also maintain consumer trust and avoid making claims that go beyond the evidence supporting their products.

For Galderma, ZO provides another route into this segment and an opportunity to expand its relationships with dermatologists, plastic surgeons and aesthetic professionals.

What the Acquisition Means for Blackstone

The deal also represents a transaction for Blackstone, the investment firm that acquired ZO Skin Health in 2020 through its tactical opportunities fund.

Private equity investors typically seek to improve a company’s operations, strengthen its market position and eventually realise the value of their investment through a sale or another transaction. The sale of ZO to Galderma transfers ownership from its existing shareholders to a strategic buyer with a business operating in the same broad dermatology and skincare ecosystem.

A strategic buyer may be able to support the business differently from a financial investor because it can integrate the brand with existing research, distribution, education and commercial capabilities.

The announced enterprise value does not, by itself, reveal Blackstone’s investment return. Calculating that return would require information about the original investment, additional capital deployed, debt and other transaction adjustments, as well as the proceeds attributable to each shareholder.

The acquisition nevertheless illustrates how private equity ownership can provide a route for established consumer-health and professional skincare brands to move into larger healthcare groups.

How Galderma Plans to Fund the Deal

Galderma said it will finance the all-cash transaction through a combination of existing cash reserves and bank financing. The funding structure means the company does not intend to pay for the acquisition by issuing new shares as the primary consideration.

The use of cash and borrowing has different implications for the balance sheet. Using cash reduces available liquidity, while debt financing increases borrowing and may raise interest expenses. The final mix will affect the company’s leverage and financing costs.

Galderma has stated that the acquisition is expected to be neutral to core earnings per share in the first full year after closing. This means it does not expect the deal to increase or decrease that measure materially over that period, based on its current assumptions.

The company also expects the transaction to be slightly dilutive to its core EBITDA margin in 2027, with the margin moving broadly in line with the group’s average from 2028 onwards. Galderma plans to increase commercial investment in the first year of ownership, with the aim of supporting renewed growth beginning in the second year after closing.

These projections indicate that the company expects some near-term investment and integration costs before the longer-term benefits become more visible. Actual performance will depend on revenue growth, operating costs, financing expenses and how effectively the two businesses work together.

Key Risks and Integration Challenges

The acquisition provides Galderma with an established professional skincare brand, but successful integration will require careful execution.

Preserving brand positioning

ZO Skin Health and Alastin have distinct product ranges and brand identities. Galderma will need to maintain those differences while finding opportunities to share research, education and distribution capabilities.

Delivering growth after investment

Galderma plans to increase commercial investment following completion. That spending may support product awareness, professional education and geographic expansion, but its return will depend on whether it generates sustainable additional sales.

Managing financing and margins

The all-cash transaction will be funded partly through bank financing. Galderma will need to manage its balance sheet while absorbing the initial effect of commercial investment and integration.

Maintaining professional relationships

ZO’s network of more than 16,500 accounts is a valuable asset. Maintaining relationships with physicians, medical spas and other distributors will be important as ownership changes.

Meeting regulatory requirements

The deal remains subject to regulatory approvals and customary closing conditions. Until the transaction closes, ZO Skin Health remains under its existing ownership arrangements.

The Bigger Picture

Galderma’s agreement to acquire ZO Skin Health reflects continued consolidation in professional skincare and dermatology. Companies with established scientific credentials, recognised brands and access to healthcare professionals can attract strategic buyers seeking to expand their portfolios and strengthen distribution.

The acquisition also demonstrates how a large dermatology group can use targeted deals to expand beyond its existing brands. For Galderma, the opportunity is to combine ZO’s professional skincare reach with its own research, commercial and international capabilities. Whether that produces lasting value will depend on growth, margins, integration and the ability to preserve customer and practitioner trust.

Looking Ahead

The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary conditions. Following completion, Galderma plans to increase commercial investment in ZO Skin Health and support the brand’s next phase of growth. Investors will be watching the funding impact, integration costs and progress against the company’s earnings and margin expectations.

The longer-term test will be whether ZO can expand its sales and profitability within Galderma’s portfolio while retaining its professional positioning. The company’s existing revenue base and international distribution network provide a starting point, but they do not guarantee growth. Subsequent financial disclosures will help establish whether the acquisition delivers the strategic and financial benefits Galderma expects.

Frequently Asked Questions

1. How much is Galderma paying for ZO Skin Health?

Galderma has agreed to acquire 100% of ZO Skin Health for an enterprise value of $1.5 billion in an all-cash transaction, subject to customary adjustments.

2. Who owns ZO Skin Health before the acquisition closes?

Its shareholders include funds managed by Blackstone Tactical Opportunities and the Obagi family.

3. How much revenue does ZO Skin Health generate?

The company reported approximately $330 million in net sales for the 12 months to June 2026.

4. When is the acquisition expected to close?

Galderma expects completion in Q4 2026 or early 2027, subject to regulatory approvals and customary closing conditions.

5. Which skincare brands does Galderma already own?

Galderma’s portfolio includes Cetaphil and Alastin, along with other dermatology and aesthetic products such as Differin, Epiduo, Dysport and Restylane.

6. Will the acquisition immediately increase Galderma’s earnings?

Not according to the company’s current outlook. Galderma expects the deal to be neutral to core earnings per share in the first full year after closing, with some near-term pressure on its core EBITDA margin.